Drug Profile
Fadrozole - Damian Pharma
Alternative Names: Dexfadrostat - Damian Pharma; DP-13Latest Information Update: 25 Jul 2022
Price :
$50
*
At a glance
- Originator Damian Pharma
- Class
- Mechanism of Action Aldosterone synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hyperaldosteronism
- No development reported Endocrine disorders
Most Recent Events
- 25 Jul 2022 phase II trial completed in Hyperaldosteronism in the Netherlands and Italy (PO, capsule) (NCT04007406) (EudraCT2019-000919-85) in May 2022
- 02 May 2022 Damian Pharma AG completes a phase II trial in Hyperaldosteronism in the Netherlands and Italy (PO, capsule) (NCT04007406) (EudraCT2019-000919-85)
- 28 Apr 2020 No recent reports of development identified for phase-I development in Endocrine-disorders(In volunteers) in United Kingdom (PO, Capsule)